Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer
Molecular Pharmaceutics · 03.06.2024 · 21 (6) · 2699-2712
DOI: 10.1021/acs.molpharmaceut.3c00983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 15.05.2024. Verfasst von Chander Parkash Dora und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Na…. Hauptthemen laut MEDLINE: Gemcitabine, Deoxycytidine, Pancreatic Neoplasms, Nanoparticles. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, University Grants Commission.
Abstract (Originalsprache)
This study aims to encapsulate gemcitabine (GEM) using a phospholipid complex (PLC) in lipid nanoparticles (NPs) to achieve several desirable outcomes, including high drug loading, uniform particle size, improved therapeutic efficacy, and reduced toxicities. The successful preparation of GEM-loaded lipid NPs (GEM-NPs) was accomplished using the emulsification-solidification method, following optimization through Box-Behnken design. The size of the GEM-NP was 138.5 ± 6.7 nm, with a low polydispersity index of 0.282 ± 0.078, as measured by a zetasizer and confirmed by transmission electron and atomic force microscopy. GEM-NPs demonstrated sustained release behavior, surpassing the performance of the free GEM and phospholipid complex. Moreover, GEM-NPs exhibited enhanced cytotoxicity, apoptosis, and cell uptake in Panc-2 and Mia PaCa cells compared to the free GEM. The in vivo pharmacokinetics revealed approximately 4-fold higher bioavailability of GEM-NPs in comparison with free GEM. Additionally, the pharmacodynamic evaluation conducted in a DMBA-induced pancreatic cancer model, involving histological examination, serum IL-6 level estimation, and expression of cleaved caspase-3, showed the potential of GEM-NPs in the management of pancreatic cancer. Consequently, the lipid NP-based approach developed in our investigation demonstrates high stability and uniformity and holds promise for enhancing the therapeutic outcomes of GEM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, sector-67, Mohali, Punjab 160062, India.
ORCID-Profile: Varun Kushwah, Sanyog Jain
Förderung
- Council of Scientific and Industrial Research, India
- University Grants Commission
Zitieren
APA
Dora, C. P., Kushwah, V., Yadav, V., Kuche, K., & Jain, S. (2024). Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer. Molecular Pharmaceutics, 21(6), 2699-2712. https://doi.org/10.1021/acs.molpharmaceut.3c00983
Vancouver
Dora CP, Kushwah V, Yadav V, Kuche K, Jain S. Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer. Molecular Pharmaceutics. 2024;21(6):2699-2712. doi:10.1021/acs.molpharmaceut.3c00983
BibTeX
@article{Dora2024,
author = {Dora, Chander Parkash and Kushwah, Varun and Yadav, Vivek and Kuche, Kaushik and Jain, Sanyog},
title = {Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {6},
pages = {2699--2712},
doi = {10.1021/acs.molpharmaceut.3c00983}
}
EUVIMED